Health Canada has recently approved an expanded use for enzalutamide (Xtandi) so that it can now be prescribed to treat men with non-metastatic castration-resistant prostate cancer (nmCRPC).
Initially being diagnosed with metastatic, or advanced prostate cancer is not great. Metastatic prostate cancer is not curable and will be terminal if you don’t die from another cause.
We now have a number of what we consider second-line treatments for prostate cancer, drugs like Zytiga, Xtandi and Taxotere (chemotherapy).
We are beginning to recognize the value of the early use of these second line drugs along with first line ADT for men who are initially diagnosed with metastatic prostate cancer.
There was a large meta-analysis recently published that compared the efficacy of abiraterone acetate (Zytiga), enzalutamide (Xtandi), cabazitaxel (Jevtana) and Radium-223 (Xofigo) in the treatment of castration-resistant, docetaxel-resistant metastatic prostate cancer.
Occasionally we hear that enzalutamide (Xtandi) increases the risk of having a seizure, especially in men who for some reason already have an increased risk. Are seizure rates in men with an increased risk factor affected by treatment with enzalutamide?
Two different trials, SPARTAN and PROSPER, are reporting top-line results in the treatment of men with nmCRPC. The full results of these trials will be presented today at the Genitourinary Cancer Symposium in San Francisco where Cancer ABCs is in attendance.
Like all of the other advanced prostate cancer treatments currently available, enzalutamide (Xtandi) lasts for a limited time. When Xtandi stops working we refer to this as developing resistance.
You have become castrate resistant and already have taken Provenge. Now, what treatment should be next? Currently, the two best options are either Zytiga (abiraterone) or Xtandi (enzalutamide). Which should come first?
Earlier studies of men with metastatic prostate cancer who took enzalutamide (Xtandi) indicated that there might be an increase in the risk having a seizure. Is this risk real? The UPWARD Study
One of the most puzzling questions faced by men with advanced prostate cancer has to do with deciding which drug to take first, Zytiga (abiraterone) or Xtandi (enzalutamide)?
It was announced that Enzalutamide (Xtandi) is the first androgen receptor-inhibitor to demonstrate a statistically significant improvement in metastasis-free survival (MFS) in men who have castrate resistant prostate cancer but do not have any confirmed metastases.